2023
Night shift work, sleep duration and endometrial cancer risk: A pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2)
Frias-Gomez J, Alemany L, Benavente Y, Clarke M, de Francisco J, De Vivo I, Du M, Goodman M, Lacey J, Liao L, Lipworth L, Lu L, Merritt M, Michels K, O'Connell K, Paytubi S, Pelegrina B, Peremiquel-Trillas P, Petruzella S, Ponce J, Risch H, Setiawan V, Schouten L, Shu X, Trabert B, Van den Brandt P, Wentzensen N, Wilkens L, Yu H, Costas L. Night shift work, sleep duration and endometrial cancer risk: A pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). Sleep Medicine Reviews 2023, 72: 101848. PMID: 37716022, PMCID: PMC10840870, DOI: 10.1016/j.smrv.2023.101848.Peer-Reviewed Original ResearchConceptsNight shift workEndometrial Cancer ConsortiumEndometrial cancer riskEndometrial cancerSleep durationShift workPostmenopausal womenPooled analysisInverse associationOdds ratioCancer riskCancer ConsortiumNon-significant inverse associationStudy-specific odds ratiosEndometrial cancer casesStrong risk factorConfidence intervalsLong sleep durationDaily sleep durationObese womenRisk factorsCancer casesLogistic regressionIndividual dataCancer
2019
P76 Prospective investigation of pre-diagnostic urinary bisphenol a and phthalates in relation to endometrial cancer risk in the multiethnic cohort (MEC) study
Sarink D, Le Marchand L, Cheng I, Wu A, Franke A, Wilkens L, White K, Yu H, Merritt M. P76 Prospective investigation of pre-diagnostic urinary bisphenol a and phthalates in relation to endometrial cancer risk in the multiethnic cohort (MEC) study. International Journal Of Gynecological Cancer 2019, 29: a101. DOI: 10.1136/ijgc-2019-esgo.138.Peer-Reviewed Original ResearchEndometrial cancer riskEndometrial cancer risk factorsCancer risk factorsMultiethnic Cohort StudyCancer riskCohort studyEndometrial cancerUrinary BPARisk factorsEndometrial cancer incidence ratesHigher body mass indexRole of BPAEndometrial cancer casesPostmenopausal hormone useAge-adjusted incidenceBody mass indexCase-control studyCancer incidence ratesConditional logistic regressionNative Hawaiian womenFrequency of casesRace/ethnicityUrinary bisphenolHormone useOral contraceptives
2014
The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLOS ONE 2014, 9: e94167. PMID: 24732316, PMCID: PMC3986055, DOI: 10.1371/journal.pone.0094167.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskType 2 endometrial cancerEndometrial cancerKRAS-variantCancer riskLymphovascular invasionSurvival outcomesTumor biologyType 1 endometrial cancerEndometrial cancer trialsOverall survival rateMiRNA expressionAge-matched controlsCase-control analysisFunctional germline variantsClinical characteristicsPatient ageTumor characteristicsCancer trialsTumor specimensSurvival rateType 1Germline variantsMiRNA expression levelsCancer
2009
Ovarian Preservation and Staging in Reproductive-Age Endometrial Cancer Patients
Richter C, Qian B, Martel M, Yu H, Azodi M, Rutherford T, Schwartz P. Ovarian Preservation and Staging in Reproductive-Age Endometrial Cancer Patients. Obstetrical & Gynecological Survey 2009, 64: 726-727. DOI: 10.1097/01.ogx.0000361368.51892.57.Peer-Reviewed Original ResearchDisease-free survivalLonger disease-free survivalSurgical stagingEndometrial cancerOvarian preservationClinical stagingPremenopausal womenEndometrial carcinomaEarly-stage low-grade endometrial cancerEarly-stage endometrial cancerEarly-stage endometrial carcinomaLow-grade endometrial cancerYoung womenLong-term adverse effectsAggressive surgical stagingGrade 1 diseaseStage endometrial cancerEndometrial cancer patientsStage 1 diseaseTotal abdominal hysterectomyEarly-stage patientsLonger overall survivalLarge university hospitalQuality of lifeParaaortic lymphadenectomy
2008
A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer
Gunter M, Hoover D, Yu H, Wassertheil-Smoller S, Manson J, Li J, Harris T, Rohan T, Xue X, Ho G, Einstein M, Kaplan R, Burk R, Wylie-Rosett J, Pollak M, Anderson G, Howard B, Strickler H. A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer. Cancer Epidemiology Biomarkers & Prevention 2008, 17: 921-929. PMID: 18398032, PMCID: PMC3090086, DOI: 10.1158/1055-9965.epi-07-2686.Peer-Reviewed Original ResearchMeSH KeywordsAgedBody Mass IndexCarcinoma, EndometrioidEndometrial NeoplasmsEstradiolFemaleHumansHypoglycemic AgentsInsulinInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 3Middle AgedMulticenter Studies as TopicObesityProportional Hazards ModelsProspective StudiesRisk FactorsConceptsInsulin-like growth factorEndometrial cancerEndometrioid adenocarcinomaRisk factorsFree IGFObese womenEstrogen levelsWomen's Health Initiative Observational StudyFree IGF-I levelsIGF-binding protein-3Growth factorBaseline serum specimensIncident endometrial cancerHormone therapy useIGF-I levelsMain histologic typesCase-cohort studyMajor risk factorHigh estrogen levelsTotal IGFPostmenopausal womenHormone therapyProspective cohortRandom subcohortTherapy use